Tell Great NonProfits how we have been doing, please

Every couple of years we ask our readers to let Great NonProfits know if we are doing a good job for you. And it’s that time again. … READ MORE …

Liquid biopsies, ctDNA, and the diagnosis and management of cancers

The American Society of Clinical Oncology (ASCO) and the College of Pathologists (CAP) have just issued a joint review of available information on clinical use of “liquid biopsies” to assess circulating levels of tumor DNA (ctDNA). … READ MORE …

Are genomic tests “up to snuff” for routine use in prognosis of prostate cancer risk?

The Intergroupe Coopérateur Francophone de Recherche en Onco-urologie (ICFuro) has just published a review of the available evidence on the clinical validity and utility of six prognostic biomarkers available for the assessment of prostate cancer-related risk. … READ MORE …

A thorough review of immunotherapeutics in the treatment of prostate cancer

A new review article has just been published in the journal Critical Reviews in Hematology Oncology. It is probably a current “must read” for support group leaders and for any patients who are interested in the idea of using immunotherapy as a treatment for progressive and advanced forms of prostate cancer. … READ MORE …

State of the art lectures at the EAU meeting in London

Recently posted on the UroToday web site are summaries of four “state-of-the-art” lectures on prostate cancer and its management presented a couple of weeks ago at the annual meeting of the European Association of Urology is London. … READ MORE …

A pathological “take” on the potential role of focal therapy

Various forms of focal therapy are now being used by some physicians to treat selected patients with well-identified, usually relatively small, “dominant” or “index” tumors that are confined to highly defined areas of the prostate. … READ MORE …

The current role of sipuleucel-T in the management of advanced prostate cancer

A new review article has provided a detailed update on the current state of knowledge about the use of sipuleucel-T (Provenge®) in the treatment of advanced forms of prostate cancer. … READ MORE …